Drug Profile
SBT 1001
Alternative Names: 14beta-Hydroxydocetaxel; 14beta-HydroxytaxotereLatest Information Update: 14 Jul 1998
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Bristol-Myers Squibb; Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Jul 1998 Profile reviewed
- 14 Jul 1998 No-Development-Reported for Cancer in USA (Unknown route)
- 02 Jun 1995 Preclinical development for Cancer in USA (Unknown route)